NCT04483622

Brief Summary

The objective of this study is to detect the evidence on the immune response following acute SARS-CoV-2 infections. the study will report the profile of IgG specific antibodies levels to SARS-CoV-2 infection found in recovered coronavirus disease (COVID-19) patients after infection for both symptomatic and asymptomatic patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 12, 2020

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

July 21, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 23, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2021

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 25, 2021

Completed
Last Updated

May 12, 2022

Status Verified

May 1, 2022

Enrollment Period

1.4 years

First QC Date

July 21, 2020

Last Update Submit

May 10, 2022

Conditions

Covid19

Keywords

COVID19 IGg

Outcome Measures

Primary Outcomes (1)

  • rising titre of IGg antibodies

    it's expected to have COVID-19 antibodies within 1month of infection the antibody titre expected to rise the fall to a lower levels

    first month

Eligibility Criteria

Age16 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients attending sohag university hospital and have recent COVID -19 infection

You may qualify if:

  • patients with recent COVID- 19 infection(2 weeks after the second negative RT-PCR assay)

You may not qualify if:

  • patients on immune-suppressive therapy
  • patients with immunological disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University Hospital

Sohag, Egypt

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor of medical microbiology and immunology at sohag faculty of medicine fa

Study Record Dates

First Submitted

July 21, 2020

First Posted

July 23, 2020

Study Start

July 12, 2020

Primary Completion

December 15, 2021

Study Completion

December 25, 2021

Last Updated

May 12, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations

EG(1)